Adalimumab for the treatment of severe psoriasis and psoriatic arthritis

Bibliography

• Prinz J. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003;17:257-70
   PubMed Web of Science ®Google Scholar
• Christophers E. Psoriasis – epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20
   PubMed Web of Science ®Google Scholar
• Lebwohl M. Psoriasis. Lancet 2003;361:1197-204
   PubMed Web of Science ®Google Scholar
• Schon MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899-912
   PubMed Web of Science ®Google Scholar
• Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 2000;9:1511-22
   PubMed Web of Science ®Google Scholar
• Crofford LJ. Psoriatic Arthritis. In: Primer on the Reumatic Diseases. 12th edition. Klippel JH, editor. Atlanta (GA): Arthritis Foundation; 2001:234-8
   Google Scholar
• Gladman DD, ShuckettR, Russel ML, et al. Psoriatic arthritis (PSA): an analysis of 220 patients. Q J Med 1987;62:127-41
   PubMedGoogle Scholar
• de Arruda LH, De Moracs AP. The impact of psoriasis in quality of life. Br J Dermatol 2001;144(Suppl 58):33-6
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
   PubMed Web of Science ®Google Scholar
• Esposito M, Saraceno R, Giunta A, et al. An Italian study on psoriasis and depression. Dermatology 2006;212:123-7
   PubMed Web of Science ®Google Scholar
• Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846-50
   PubMed Web of Science ®Google Scholar
• Gupta MA, Schork NJ, Gupta AK, et al. Suicidal ideation in psoriasis. Int J Dermatol 1993;32:188-90
   PubMed Web of Science ®Google Scholar
• Pearce DJ, Morrison AE, Higgins KB, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005;16(5-6):319-23
   PubMed Web of Science ®Google Scholar
• Tristani-Firouzi P, Krueger GG. Efficacy and safety of tretment modalities for psoriasis. Cutis 1998;61:11-21
   PubMed Web of Science ®Google Scholar
• Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000;25:1-10
   PubMed Web of Science ®Google Scholar
• Sterry W, Barker J, Boehncke WH, et al. Biologicals in psoriasis consensus. Br J Dermatol 2004;151(Suppl 69):3-17
   PubMed Web of Science ®Google Scholar
• da Silva AJ, Brickelmaier M, Majeau GR, et al. Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2+ cells. J Immunol 2002;168:4462-71
   PubMed Web of Science ®Google Scholar
• Piascik P. Alefacept, first biologic agent approved for treatment of psoriasis. J Am Pharm Assoc 2003;43:649-50
   Google Scholar
• Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27
   PubMed Web of Science ®Google Scholar
• Jullien D, Prinz JC, Langley RG, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004;208(4):297-306
   PubMed Web of Science ®Google Scholar
• Raptiva, Product information. Available at: URL: www.kompendium.ch [Accessed February 2008]
   Google Scholar
• Raptiva EMEA approved product information. Available at: URL: www.emea.europa.eu/ [Accessed February 2008]
   Google Scholar
• Gupta AK, Cherman AM. Efalizumab in the treatment of psoriasis. J Cutan Med Surg 2006;10:57-68
   PubMed Web of Science ®Google Scholar
• Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10:1-252
   PubMedGoogle Scholar
• Boss JD, de Rie MA. The pathogenesis of psoriasis: immunological facts and speculations. Immunol Today 1999;20:40-6
   PubMedGoogle Scholar
• Ettehadi P, Greaves MW, Wallach D, et al. Elevated tumor necrosis factor-α (TNFα) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96:146-51
   PubMed Web of Science ®Google Scholar
• Hohler T, Krueger A, Schneider PM, et al. A TNF-α promoter polimorphism is associated with juvenile onset of psoriasis and psoriatic arthritis. J Invest Dermatol 1997;109:562-5
   PubMed Web of Science ®Google Scholar
• Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24:518-23
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Haas-Smith SA, Hicks D, et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25:1544-52
   PubMed Web of Science ®Google Scholar
• Danning CL, Illei GG, Hitchon C, et al. Macrophege-derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000;43:1244-56
   PubMed Web of Science ®Google Scholar
• Partsch C, Wagner E, Leeb BF, et al. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis sinovial fluid. J Rheumatol 1998;25:105-10
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). European Public Assessment Report on Enbrel. Available at: URL: www.emea.europa.eu/humandocs/PDFs/EPAR/Enbrel/H-262-PI-en.pdf [Accessed 31 July 2007]
   Google Scholar
• Mease P. Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept. Clin Exp Rheumatol 2002;20(6 Suppl 28):116-21
   PubMedGoogle Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304-12
   PubMed Web of Science ®Google Scholar
• Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35
   PubMed Web of Science ®Google Scholar
• Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 2005;45:490-7
   PubMed Web of Science ®Google Scholar
• Nestorov I, Zitnik R, Ludden T. Population pharmacokinetic modeling of subcutaneously administered etanercept in patients with psoriasis. J Pharmacokinet Pharmacodyn 2004;31:463-90
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51:534-42
   PubMed Web of Science ®Google Scholar
• Oh CJ, Das KM, Gottlieb AB. Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000;42(5 Pt 1):829-30
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31-15
   PubMed Web of Science ®Google Scholar
• Salfeld J, Kaymakcalan Z, Traccy D, et al. Generation of fully human anti- TNF antibody D2E7. Arthritis Rheum 1998;41(Suppl):57 (Abstract)
   Web of Science ®Google Scholar
• Humira [package insert]. Abbott park, Ill. Abbott
   Google Scholar
• Gordon KB, Bonish BK, Patel T, et al. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005;153:945-53
   PubMed Web of Science ®Google Scholar
• Seitz M, Wirthmuller U, Moller B, et al. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007;46:93-6
   PubMed Web of Science ®Google Scholar
• Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005;52:2693-6
   PubMed Web of Science ®Google Scholar
• Mease P, Gladman D, Ritchlin C, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Artthitis Reum 2005;52:3279-89
   PubMed Web of Science ®Google Scholar
• Gladman D, Mease P, Ritchlin C, et al. Adalimumab for long-term treatment of psoriatic arthritis. Forty-eight week data from the adalimumab effectivness in psoriatic arthritis trials. Artthitis Reum 2007;56:476-88
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606
   PubMed Web of Science ®Google Scholar
• Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J Dermatolog Treat 2007;18:25-31
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007;57:269-75
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring S, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15
   PubMed Web of Science ®Google Scholar
• Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2007;In Press
   Google Scholar
• Sladden MJ, Mortimer NJ, Hutchinson PE. Extensive plaque psoriasis succesfully treated with adalimumab (Humira®). Br J Dermatol 2005;152:1062-94
   PubMed Web of Science ®Google Scholar
• Chew AL, Bennett A, Smith CH, et al. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol 2004;151:492-6
   PubMed Web of Science ®Google Scholar
• Pitarch G, Sanchez-Carazo JL, Mahiques L, Perez-Ferriols MA, Fortea JM. Treatment of psoriasis with adalimumab. Clin Exp Dermatol 2007;32(1):18-22
   PubMed Web of Science ®Google Scholar
• Tobin AM, Kirbi B. Successful treatment of recalcitrant acrodermatitis continua di Hallopeau with adalimumab and acitretin. Br J Dermatol 2005;153:440-6
   PubMed Web of Science ®Google Scholar
• Callen JP, Jackson JH. Adalimumab effectively controlled recalcitrant generalized pustular psoriasis in an adolescent. J Dermatolog Treat 2005;16:350-2
   PubMed Web of Science ®Google Scholar
• Schopf RE, Beis E. Adalimumab treatment clears localized pustular psoriasis of palms and soles. J Invest Dermatol 2007;127(S1):S50 Abstract 296
   Google Scholar
• Zangrilli A, Papoutsaki M, Talamonti M, et al. Long term efficacy of adalimumab in generalized pustolar psoriasis. J Dermatol Treat In press
   PubMedGoogle Scholar
• Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-α therapy. Rheumatology (Oxford) 2007;46:695-8
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. Adalimumab: a review of side effects. Expert Opin Drug Saf 2005;4(4):637-41
   PubMedGoogle Scholar
• de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31
   PubMed Web of Science ®Google Scholar
• Berthelot CN, George SJ, Hsu S. Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol 2005;53(5 Suppl 1):260-2
   PubMed Web of Science ®Google Scholar
• Chung JH, Van Stavern GP, Frohman LP, et al. Adalimumab-associated optic neuritis. J Neurol Sci 2006;244:133-6
   PubMed Web of Science ®Google Scholar
• George SJ, Anderson HL, Hsu S. Adalimumab-induced urticaria. Dermatol Online J 2006;12(2):4
   PubMedGoogle Scholar
• Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor α inhibitors. Arch Dermatol 2006;142:198-202
   PubMed Web of Science ®Google Scholar
• Tubach F, Ravaud P, Salmon-Ceron D, et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-α antagonists. Clin Infect Dis 2006;43:95-100
   PubMed Web of Science ®Google Scholar
• Saint Marcoux B, De Bandt M; CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFα antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73:710-3
   PubMed Web of Science ®Google Scholar
• Fulchiero GJ Jr, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol 2007;56(5 Suppl):65-7
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005;52:2513-8
   PubMed Web of Science ®Google Scholar
• Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 2006;65:405-7
   PubMedGoogle Scholar
• Aslanidis S, Pyrpasopoulou A, Leontsini M, et al. Anti-TNF-α-induced psoriasis: case report of an unusual adverse event. Int J Dermatol 2006;45:982-3
   PubMed Web of Science ®Google Scholar
• Goiriz R, Dauden E, Perez-Gala S, et al. Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers. Clin Exp Dermatol 2007;32:176-9
   PubMed Web of Science ®Google Scholar